YOLFTbeta
00

Yantai Dongcheng Pharmaceutical Co Ltd

002675 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

12.74CNY-0.14 (-1.09%)

Price History

Full chart

Market Stats

Previous Close12.88
Open12.83
Day Range12.67 – 12.93
52-Week Range12.05 – 16.04
Volume6.00M
Market Cap10.64B
P/E (TTM)53.75
Forward P/E0.00
EPS0.24
Dividend Yield0.62%
Beta-0.12
50-Day Avg12.84
200-Day Avg13.19

About

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. engages in the raw materials, formulations, nuclear medicine, and big health businesses in China and internationally. It operates through API, Formulation, Radio Pharmaceutical, and Others segments. The company offers formulation products, such as powder injections, tablets, capsules, granules, and drop pills for anticoagulation, cardiovascular, anti-tumor, urology, orthopedics, and anti-infection applications. It also provides active pharmaceutical ingredients, including heparin, chondroitin sulfate sodium and calcium, hyaluronic acid, cytochrome C, and collagen, as well as glucosamine hydrochloride, glucosamine sulfate sodium chloride, and glucosamine sulfate potassium chloride; and nadroparin calcium for injection, hydrocortisone sodium succinate for injection, chorionic gonadotrophin for injection, menotropins for injection, ambroxol hydrochloride dispersible tablets, jinjunling capsules, metformin hydrochloride and glibenclamide tablets, clemastine fumarate tablets, and wind-dispelling itch-relieving granules. In addition, the company offers Technetium Methylene Diphosphonate injections; Technetium Tc=labeled tracers; 2-[18F]FDG for early diagnosis of tumors; sodium iodide oral solution; iodine seeds used for internal radiation treatment of various malignant tumors; urea capsules; and jiabaolin glucosamine chondroitin sulfate capsules. Further, it engages in trading; medical technology; medical devices; technical services; biotechnology service promotion; medical research and experimental development; business services; enterprise management, business information, and financial consulting; multimodal transport and transport agency services; capital market services; operation of local platforms for images; and engineering activities. The company exports its products to approximately 40 countries and regions. Yantai Dongcheng Pharmaceutical Group Co.,Ltd. was founded in 1998 and is headquartered in Yantai, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Zhi Gang Luo
  • Employees2.58K
  • HeadquartersNo.7 Changbaishan Road, Yantai, China, 264006, China
  • Websitehttps://www.dcb-group.com

Leadership

  • Mr. Zhi Gang LuoGM & Non-Independent Director · b. 1970
  • Ms. Chun Ping ZhuChief Financial Officer · b. 1965
  • Ms. Sai YouDeputy GM & Non-Independent Director · b. 1986
  • Mr. Xiao Jie LiuDeputy GM, Board Secretary & Director · b. 1982
  • Mr. Chun Xiang LuDeputy General Manager · b. 1975
  • Ms. Jing SunDeputy General Manager · b. 1970
  • Jing ZhouAccounting Supervisor

Financials

Income Statement

Currency: CNY2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue323.39M376.46M663.63M857.57M587.75M774.73M751.02M794.92M1.16B1.60B2.33B2.99B3.42B3.91B3.58B3.28B2.87B2.72B
Growth (%)-+16.41%+76.28%+29.22%-31.46%+31.81%-3.06%+5.84%+45.73%+37.74%+46.20%+28.29%+14.24%+14.42%-8.41%-8.58%-12.42%-5.10%
Cost of Revenue277.51M314.36M565.66M656.16M414.75M594.51M504.74M493.80M612.97M727.15M1.00B1.22B1.76B2.32B2.05B1.92B1.52B1.42B
Gross Profit45.88M62.10M97.97M201.41M173.00M180.22M246.28M301.12M545.48M868.45M1.33B1.77B1.66B1.59B1.53B1.35B1.35B1.30B
Gross Margin14.19%16.50%14.76%23.49%29.43%23.26%32.79%37.88%47.09%54.43%57.07%59.31%48.65%40.59%42.77%41.34%46.97%47.70%
Operating Expense29.07M25.63M38.67M56.60M55.99M83.60M119.85M172.95M305.83M554.28M863.89M1.38B1.05B1.23B1.08B1.01B1.13B946.32M
Operating Income16.81M36.47M59.30M144.81M117.01M96.62M126.43M128.17M239.65M314.17M467.57M393.77M609.14M356.93M448.25M341.66M220.81M352.30M
Operating Margin5.20%9.69%8.94%16.89%19.91%12.47%16.83%16.12%20.69%19.69%20.04%13.16%17.82%9.12%12.51%10.43%7.70%12.94%
EBITDA34.38M48.79M75.11M167.82M126.51M110.62M144.45M148.52M262.51M415.67M586.92M749.52M727.85M727.92M672.09M511.69M432.69M572.16M
EBITDA Margin10.63%12.96%11.32%19.57%21.53%14.28%19.23%18.68%22.66%26.05%25.16%25.04%21.29%18.61%18.76%15.62%15.08%21.02%
Net Income15.07M31.99M50.64M127.94M105.06M100.85M103.96M89.75M130.95M172.63M280.43M154.71M417.77M151.56M307.29M209.74M183.83M195.63M
Net Income Margin4.66%8.50%7.63%14.92%17.87%13.02%13.84%11.29%11.30%10.82%12.02%5.17%12.22%3.87%8.58%6.40%6.41%7.19%
R&D313.60K319.40K2.56M4.84M30.28M15.36M37.43M38.14M42.18M57.52M64.78M88.71M109.39M137.56M163.52M197.22M298.93M203.78M
R&D as % of Total Revenue0.10%0.08%0.39%0.56%5.15%1.98%4.98%4.80%3.64%3.60%2.78%2.96%3.20%3.52%4.56%6.02%10.42%7.48%
Interest Expense13.16M4.56M7.76M8.34M123.98K1.57M3.45M7.33M19.40M35.68M55.01M60.63M51.48M59.03M61.99M59.32M98.23M138.94M
Interest Expense % of Total Revenue4.07%1.21%1.17%0.97%0.02%0.20%0.46%0.92%1.67%2.24%2.36%2.03%1.51%1.51%1.73%1.81%3.42%5.10%

Balance Sheet

Currency: CNY2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets195.09M266.96M359.19M451.24M1.09B1.23B1.39B2.55B4.27B5.27B6.97B7.29B7.39B7.66B8.18B8.08B8.63B9.26B
Total Liabilities115.74M126.53M168.14M146.82M72.84M127.18M209.06M311.94M1.18B1.98B2.36B2.52B2.43B2.63B2.89B2.69B3.26B3.61B
Total Equity75.88M140.23M190.87M304.22M1.02B1.09B1.17B2.05B2.77B2.90B4.18B4.29B4.47B4.40B4.75B4.78B4.48B4.35B
Cash10.52M9.80M62.80M125.17M620.15M215.69M161.18M319.60M810.36M377.52M911.49M824.76M715.79M826.61M1.02B644.42M755.97M870.75M
Total Debt32.16M101.36M122.50M85.92M1.80M47.53M97.91M146.35M666.83M1.18B1.24B865.01M912.17M1.05B635.60M792.23M784.62M2.61B
Net Debt51.64M91.56M59.70M-39.25M-618.35M-168.16M-63.27M-173.24M-143.53M800.14M235.02M22.55M196.38M163.10M-386.03M106.23M28.65M1.74B

Cash Flow

Currency: CNY2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow41.57M-26.60M57.02M138.83M44.53M-20.60M52.00M66.69M196.28M208.94M493.06M696.38M572.58M943.58M996.54M276.94M287.15M584.61M
Investing Cash Flow-5.70M-44.80M-16.05M-17.72M-71.96M-399.42M-132.46M-12.21M-549.65M-1.13B72.80M-209.58M-530.72M-739.25M-452.75M-602.80M-715.00M-559.43M
Financing Cash Flow-33.75M73.94M13.88M-59.40M520.12M16.77M24.65M95.03M840.28M428.92M4.22M-552.89M-141.49M-188.68M-359.13M-676.00K543.58M86.32M
Capital Expenditure5.30M23.57M16.05M17.73M71.96M173.13M66.50M82.04M131.17M143.93M121.05M250.08M262.19M530.16M389.61M511.94M456.09M360.82M
Free Cash Flow36.26M-50.17M40.96M121.10M-27.43M-193.73M-14.50M-15.36M65.11M65.01M372.01M446.30M310.39M413.42M606.92M-235.00M-168.94M223.79M
Dividends Paid6.78M15.63M7.78M22.98M35.13M28.56M25.30M34.85M50.46M84.39M132.82M246.53M347.61M302.48M251.24M258.33M217.25M24.74M
FCF to OCF87.24%188.60%71.84%87.23%-61.59%940.31%-27.88%-23.03%33.17%31.11%75.45%64.09%54.21%43.81%60.90%-84.85%-58.83%38.28%
Dividend Paid to FCF18.69%-31.15%18.99%18.97%-128.09%-14.74%-174.53%-226.99%77.50%129.80%35.70%55.24%111.99%73.16%41.40%-109.93%-128.60%11.05%

Earnings

Report DateJun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Oct 27, 2014Feb 5, 2015Apr 17, 2015Jul 20, 2015Oct 29, 2015Feb 26, 2016Apr 26, 2016Jul 27, 2016Oct 26, 2016Mar 1, 2017Apr 25, 2017Aug 9, 2017Oct 23, 2017Feb 27, 2018Apr 25, 2018Aug 10, 2018Oct 26, 2018Jan 31, 2019Apr 23, 2019Jul 30, 2019Oct 28, 2019Feb 21, 2020Apr 17, 2020Aug 6, 2020Oct 26, 2020Dec 31, 2020Apr 29, 2021Jul 27, 2021Oct 28, 2021Dec 31, 2021Apr 28, 2022Aug 25, 2022Oct 27, 2022Dec 31, 2022Apr 28, 2023Aug 23, 2023Oct 26, 2023Apr 26, 2024Aug 30, 2024Oct 29, 2024Apr 29, 2025Aug 14, 2025Oct 29, 2025Mar 25, 2026Apr 28, 2026Aug 21, 2026
EPS Estimate----------0.06-0.060.050.11-----0.110.11---------------------------0.16-0.090.070.160.080.08
EPS Actual0.130.050.030.070.050.040.040.050.060.040.050.050.050.040.030.030.060.190.050.040.030.030.050.060.100.110.100.080.140.13-0.150.090.180.150.100.080.110.13-0.140.070.140.20-0.030.060.160.12-0.090.060.070.020.080.060.060.040.07
Surprise-----------16.67%--16.67%-20.00%-72.73%------72.73%-72.73%----------------------------87.50%188.89%-14.29%-62.50%-54.63%-12.50%
Timing---------After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-market-After-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketAfter-hours-Pre-marketAfter-hoursPre-marketPre-marketPre-market-After-hoursAfter-hours-After-hours-After-hours

Key Statistics & Ratios

Market Cap10.64B
Enterprise Value10.96B
Trailing P/E53.75
Forward P/E0.00
PEG Ratio0.00
Price / Sales3.99
Price / Book2.39
EPS0.24
Book Value5.33
Revenue (TTM)2.67B
Gross Profit (TTM)1.43B
EBITDA556.03M
Profit Margin7.53%
Operating Margin15.92%
Return on Equity3.10%
Return on Assets2.59%
Shares Outstanding824.60M
Shares Float470.12M
Beta-0.12
Dividend Yield0.62%
Dividend Rate0.08
Payout Ratio35.63%

Dividends

20261×
0.08Apr 29, 2026
20251×
0.03May 27, 2025
20242×
0.05Dec 19, 20240.13Jun 24, 2024
20231×
0.15Jul 10, 2023
20221×
0.15Jun 9, 2022
20211×
0.25Jun 4, 2021
20201×
0.25May 27, 2020
20191×
0.05Apr 24, 2019
20181×
0.03May 24, 2018
20171×
0.04Jun 16, 2017
20161×
0.04May 20, 2016
20151×
0.05May 15, 2015
20141×
0.04Jul 15, 2014
20131×
0.05Jul 1, 2013

Stock Splits

  • Aug 30, 201630:10
  • Jul 1, 201316:10